Avidity Biosciences Stock Performance
| RNA Stock | USD 72.65 0.18 0.25% |
On a scale of 0 to 100, Avidity Biosciences holds a performance score of 11. The firm shows a Beta (market volatility) of 1.06, which signifies a somewhat significant risk relative to the market. Avidity Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Avidity Biosciences is expected to follow. Please check Avidity Biosciences' downside variance, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Avidity Biosciences' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Avidity Biosciences are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Avidity Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.25 | Five Day Return 0.0689 | Year To Date Return 0.76 | Ten Year Return 154.91 | All Time Return 154.91 |
1 | Primrose Bio Launches Prima RNApols ExTend Cap AU, a Next-Gen RNA Polymerase for Self-Amplifying mRNA | 11/10/2025 |
2 | Disposition of 1542 shares by Hughes Steven George of Avidity Biosciences at 46.66 subject to Rule 16b-3 | 11/28/2025 |
3 | Hummingbird Diagnostics Publishes Study on RNA Biomarker Methylation in Liquid Biopsies | 12/16/2025 |
4 | Disposition of 29159 shares by Sarah Boyce of Avidity Biosciences subject to Rule 16b-3 | 12/18/2025 |
5 | Assenagon Asset Management S.A. Has 2 Million Holdings in Avidity Biosciences, Inc. RNA - MarketBeat | 12/24/2025 |
6 | Gene Therapy RD Market Forecast Report 2025-2035 Focus on Cancer, Rare Diseases, Cardiovascular, Ophthalmic, Haematology, Neurological, Diabetes Mellitus | 01/05/2026 |
7 | Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease | 01/07/2026 |
8 | STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications | 01/08/2026 |
9 | Disposition of 15000 shares by Teresa McCarthy of Avidity Biosciences at 22.34 subject to Rule 16b-3 | 01/09/2026 |
10 | Acquisition by Eric Mosbrooker of 72000 shares of Avidity Biosciences subject to Rule 16b-3 | 01/12/2026 |
11 | Genetic Modification Therapies Set to Surge, Market Valued at 32.1 Billion by 2030 | 01/15/2026 |
12 | Strategic Insights into RNA Therapy Adapting to Regulatory Changes and Supply Chain Shifts for Sustained Growth | 01/16/2026 |
13 | Exploring Investment Opportunities in the Expanding RNA Therapy Clinical Trials Market A USD 4.28 Billion Valuation by 2031 | 01/21/2026 |
| Begin Period Cash Flow | 185.4 M | |
| Total Cashflows From Investing Activities | -854.2 M |
Avidity Biosciences Relative Risk vs. Return Landscape
If you would invest 4,915 in Avidity Biosciences on October 24, 2025 and sell it today you would earn a total of 2,350 from holding Avidity Biosciences or generate 47.81% return on investment over 90 days. Avidity Biosciences is generating 0.7693% of daily returns assuming volatility of 5.475% on return distribution over 90 days investment horizon. In other words, 49% of stocks are less volatile than Avidity, and above 85% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Avidity Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avidity Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Avidity Biosciences, and traders can use it to determine the average amount a Avidity Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1405
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RNA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Avidity Biosciences is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avidity Biosciences by adding it to a well-diversified portfolio.
Avidity Biosciences Fundamentals Growth
Avidity Stock prices reflect investors' perceptions of the future prospects and financial health of Avidity Biosciences, and Avidity Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avidity Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (15.13) % | ||||
| Current Valuation | 9.09 B | ||||
| Shares Outstanding | 150.68 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 5.79 X | ||||
| Price To Sales | 523.26 X | ||||
| Revenue | 10.9 M | ||||
| Gross Profit | (467.32 M) | ||||
| EBITDA | (376.16 M) | ||||
| Net Income | (322.3 M) | ||||
| Cash And Equivalents | 398.22 M | ||||
| Cash Per Share | 7.64 X | ||||
| Total Debt | 6.8 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.00 X | ||||
| Book Value Per Share | 12.85 X | ||||
| Cash Flow From Operations | (300.87 M) | ||||
| Earnings Per Share | (4.19) X | ||||
| Market Capitalization | 10.92 B | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (893.07 M) | ||||
| Working Capital | 1.44 B | ||||
| Current Asset | 50.65 M | ||||
| Current Liabilities | 16.97 M | ||||
About Avidity Biosciences Performance
By analyzing Avidity Biosciences' fundamental ratios, stakeholders can gain valuable insights into Avidity Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Avidity Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avidity Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.19) | |
| Return On Capital Employed | (0.30) | (0.28) | |
| Return On Assets | (0.21) | (0.19) | |
| Return On Equity | (0.26) | (0.25) |
Things to note about Avidity Biosciences performance evaluation
Checking the ongoing alerts about Avidity Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Avidity Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avidity Biosciences is way too risky over 90 days horizon | |
| Avidity Biosciences appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 10.9 M. Reported Net Loss for the year was (322.3 M) with loss before taxes, overhead, and interest of (467.32 M). | |
| Avidity Biosciences has about 398.22 M in cash with (300.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics Stock |
- Analyzing Avidity Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avidity Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Avidity Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avidity Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avidity Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avidity Biosciences' stock. These opinions can provide insight into Avidity Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Avidity Stock analysis
When running Avidity Biosciences' price analysis, check to measure Avidity Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avidity Biosciences is operating at the current time. Most of Avidity Biosciences' value examination focuses on studying past and present price action to predict the probability of Avidity Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avidity Biosciences' price. Additionally, you may evaluate how the addition of Avidity Biosciences to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |